# Amicus Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Amicus Therapeutics, Inc.).

## Overview

Amicus Therapeutics, Inc. is a U.S.-based biotechnology company focused on medicines for rare diseases, with commercial franchises in Fabry disease and late-onset Pompe disease. Its marketed products include Galafold® (migalastat), an oral therapy for Fabry patients with amenable genetic variants, and the two-component Pompe regimen Pombiliti® + Opfolda® (cipaglucosidase alfa-atga/miglustat). The company sells globally through specialty distributors and pharmacies, with reimbursement and government payors playing a central role in access and pricing. Amicus also expands its pipeline via partnering and licensing, including an exclusive U.S. commercialization license for Dimerix’s Phase 3 candidate DMX-200 for FSGS and other indications.

## Products & services

• Galafold® (migalastat) for Fabry disease (amenable variants)
• Pombiliti® + Opfolda® for late-onset Pompe disease
• DMX-200 (licensed) U.S. commercialization rights (Phase 3, FSGS)
• Rare-disease R&D (next-generation therapies, novel technologies)
• Global regulatory, market access, and reimbursement execution

- **Galafold (Fabry disease)** (80%) — Oral precision therapy for Fabry patients with amenable genetic variants, sold commercially across multiple countries.
- **Pombiliti + Opfolda (Pompe disease)** (17%) — Two-component therapy for adults with late-onset Pompe disease, with approvals and reimbursement expansion underway globally.
- **Pipeline and partnered programs (e.g., DMX-200)** (3%) — Clinical-stage and in-licensed assets where Amicus funds development/regulatory work and prepares for commercialization in targeted markets.

- Galafold® (migalastat) for Fabry disease (amenable variants)
- Pombiliti® + Opfolda® for late-onset Pompe disease
- DMX-200 (licensed) U.S. commercialization rights (Phase 3, FSGS)
- Rare-disease R&D (next-generation therapies, novel technologies)
- Global regulatory, market access, and reimbursement execution

## Customers

Amicus’s direct customers are typically specialty distributors and pharmacies that purchase Galafold® and Pombiliti® + Opfolda® and take control of product at delivery. Demand is driven by specialist physicians and treatment centers that diagnose and prescribe therapies for Fabry and Pompe disease, while access is heavily shaped by third-party payors and government reimbursement programs. Because these are rare diseases, patient identification, genetic testing (for Galafold amenability), and ongoing patient support are important to therapy uptake and persistence. Patient organizations and charitable foundations can influence awareness, access pathways, and affordability support, which makes compliant engagement a meaningful part of the commercial model.

- **Specialty distributors and pharmacies** (primary) — Buy Galafold and Pombiliti + Opfolda for downstream dispensing; central to order flow and channel inventory dynamics.
- **Specialist prescribers and treatment centers** (primary) — Drive initiation and switching decisions based on efficacy, safety, convenience, and clinical guidelines for Fabry/Pompe.
- **Third-party payors and government authorities** (primary) — Approve coverage, set reimbursement terms, and generate rebates/discounts that materially affect net product sales.
- **Patients, patient organizations, and foundations** (secondary) — Influence diagnosis journeys, therapy selection, and affordability support; important for rare-disease adoption and persistence.

- Specialty distributors and pharmacies purchase product inventory
- Metabolic/neuromuscular specialists prescribe Fabry and Pompe therapies
- Hospitals/infusion centers administer Pompe ERT component (Pombiliti)
- Government and private payors determine reimbursement and net price
- Patients and caregivers influence adherence and therapy choice
- Patient organizations/foundations support awareness and access programs

## Geography

Amicus commercializes Galafold® in over 40 countries, including the United States, European Union, United Kingdom, and Japan, reflecting a broad rare-disease footprint beyond a single market. Pombiliti® + Opfolda® is approved in the U.S., E.U., U.K., Canada, Australia, Switzerland, and Japan, with additional submissions and reimbursement processes ongoing. Manufacturing is largely outsourced to contract manufacturers under cGMP, creating operational dependence on external supply chains rather than company-owned plants. The company is working with WuXi on a second manufacturing facility for Pombiliti® in Dundalk, Ireland, which introduces regulatory-approval and execution considerations across jurisdictions.

- Galafold approved across U.S., E.U., U.K., Japan and 40+ countries
- Pombiliti + Opfolda approved in U.S., E.U., U.K., CA, AU, CH, JP
- Reimbursement expansion in multiple E.U. countries supports uptake
- Supply chain relies on global contract manufacturers under cGMP
- Second Pombiliti facility under development in Dundalk, Ireland (WuXi)
- Multi-jurisdiction regulation (FDA/EMA/PMDA) shapes timelines and costs

## Strategy

Amicus is prioritizing growth of its two commercial franchises by expanding geographic reach, securing reimbursement, and deepening penetration in Fabry and Pompe patient populations. The company is also advancing next-generation therapies and novel technologies to extend its rare-disease platform beyond current products. Business development is a core lever, with management explicitly evaluating collaborations, in-licensing, and acquisitions to add marketed or late-stage assets aligned to rare and orphan diseases. The DMX-200 license illustrates a strategy of acquiring U.S. commercialization rights to a late-stage program while the partner continues to run the pivotal study, allowing Amicus to focus on regulatory submission and commercial build-out.

- **Broaden Fabry and Pompe commercial franchises globally** (short-term) — Rare-disease revenue growth depends on approvals, reimbursement, and patient identification across countries.
- **Add pipeline value through business development and licensing** (medium-term) — In-licensed or acquired assets can diversify beyond two products and extend growth runway in rare/orphan diseases.
- **Strengthen manufacturing resilience via qualified supply options** (medium-term) — Outsourced manufacturing and regulatory approvals can constrain supply and limit commercial execution if not de-risked.

- Expand Galafold commercial momentum and enter additional geographies
- Scale Pompe franchise via approvals and reimbursement agreements
- Invest in next-generation therapies and novel rare-disease technologies
- Pursue business development (in-licensing, partnerships, acquisitions)
- Prepare U.S. regulatory dossier and commercialization for DMX-200 (FSGS)
- Leverage global capabilities across regulatory, access, and distribution

## Risks

Amicus’s revenue base is concentrated in two rare-disease products, so competitive entries, label changes, or reimbursement pressure can have an outsized impact on growth and pricing. The company relies on third-party manufacturers for active ingredients and finished goods, making it exposed to cGMP compliance, capacity constraints, and regulatory approval risk for new or expanded facilities (including the planned second Pombiliti site in Ireland). Commercial execution depends on distributors and pharmacies, and the company highlights risks around distributor performance, financial health, compliance, and potential disruption if agreements terminate. Like other biotech companies, Amicus faces ongoing regulatory, clinical-development, and cybersecurity risks, including vendor/supply-chain cyber incidents that could disrupt operations or trigger disclosure and reputational harm.

- **Regulatory approval delays or failure for second Pombiliti facility (Dundalk, Ireland)** [high] — Although EMA approved, the facility may not be approved by FDA/other regulators, potentially delaying supply resilience and requiring additional capital.
- **Distributor dependency and potential disruption of commercialization** [high] — Distributors may underinvest, face financial/compliance issues, or terminate/expire arrangements, interrupting sales and reducing revenue.
- **Cybersecurity incidents impacting Amicus or key vendors/manufacturers** [medium] — Attacks could lead to data loss, ransomware costs, operational disruption, and reputational harm; supply-chain incidents can have similar effects.
- **Failure to complete the pending transaction with BioMarin** [medium] — Non-completion within expected timeframe or at all could adversely affect business, financial results, and operations.

- Third-party manufacturing dependence (cGMP, capacity, quality, delays)
- FDA approval uncertainty for new Pombiliti facility in Ireland (WuXi)
- Distributor risks: performance, financial distress, compliance issues
- Reimbursement and government program rebates/discounts pressure net sales
- Small patient populations make market-size estimates and uptake uncertain
- Competition from ERTs, next-gen ERTs, and gene therapies in LSDs
- Cybersecurity incidents at Amicus or vendors could disrupt operations
- Execution risk on business development (e.g., DMX-200 milestones/royalties)

## Accounting

Amicus’s net product sales are recognized at a point in time when distributors or pharmacies obtain control of product, which makes quarter-to-quarter results sensitive to channel ordering patterns and inventory levels. Reported revenue is reduced by variable consideration estimates, primarily rebates and discounts tied to U.S. and foreign government programs and other payer arrangements; these estimates require judgment about customer mix, statutory terms, and expected claims. Management highlights that financial statements rely on significant estimates and assumptions, so changes in inputs can affect reported assets, liabilities, and period results. The company also has exposure to foreign exchange remeasurement on foreign-denominated balances, which can create volatility in other income/expense separate from operating performance.

- **Product revenue recognition and variable consideration estimates** — Affects reported net revenue, gross-to-net adjustments, and period comparability
- **Foreign exchange remeasurement** — Introduces non-operating volatility that can obscure underlying operating trends

- Revenue recognized when distributors/pharmacies obtain control (point-in-time)
- Net sales reduced by estimated rebates/discounts (variable consideration)
- Estimates depend on customer mix, statutory terms, and channel inventory
- Risk of revenue true-ups if actual rebates/discounts differ from estimates
- FX remeasurement of foreign-denominated balances affects other income/expense
- Income taxes depend on jurisdictional mix and timing differences

---

*Last updated: 2026-08-11T04:46:17.914716+00:00*